Tafamidis
- Generic Name
- Tafamidis
- Brand Names
- Vyndamax, Vyndaqel
- Drug Type
- Small Molecule
- Chemical Formula
- C14H7Cl2NO3
- CAS Number
- 594839-88-0
- Unique Ingredient Identifier
- 8FG9H9D31J
- Background
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal.
Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
- Indication
Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
- Associated Conditions
- Cardiomyopathy
- Associated Therapies
- -
Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00935012
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 93
- Registration Number
- NCT00925002
- Locations
- 🇵🇹
Unidade Clinica de Paramiloidose Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António, Porto, Portugal
🇸🇪FAP-Teamet Familjar Amyloidos, Umea, Sweden
🇩🇪Universitatsklinikum Muenster, Muenster, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.